Based on the findings of this study, a pivotal phase 2 study (NCT04641754) is ongoing to further inform the therapeutic potential of WX-0593 in advanced NSCLC patients with ALK or ROS1 rearrangements. Here, ALK is linked to non-small cell lung carcinoma.